Whitehawk Therapeutics (NASDAQ: WHWK) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 73.68 percent increase over losses of $(0.76) per share from the same period last year.